A novel series of carbamothioylamino-benzene-sulfonamidethiophene-carboxylates 4a-c and thieno [3,2-d]pyrimidin-2-yl-amino-benzene-sulfonamides 5a-c were synthesized in a series of synthetic steps and were used as key intermediates for the synthesis of thienotriazolopyrimidine-benzene-sulfonamide derivatives 6a-c and 7a-c. Thieno[3,2-d]pyrimidinones (8 and 9) were also prepared. Compound 9 was used as an intermediate for the synthesis of imidazole/1,2,4-triazole and tetrazine functionalized thieno[3,2-d]pyrimidine derivatives (10-12). Pyrrole derivatives/pyrrolopyrimidine/pyrrolotriazolopyrimidine functionalized thiophenes (15-19) were also synthesized. Structures of the newly synthesized compounds were established by elemental analysis and spectral data. Most of the newly synthesized compounds were evaluated for their in vitro activity against three human tumor cell lines, namely, liver cancer (HepG-2), colon cancer (HT-29) and lung cancer (NCI-H460), using doxorubicin as standard. , resp.) showed higher activity against all cell lines than doxorubicin. Most of the compounds were also screened for antibacterial activity using ciprofl oxacin as standard drug. Compounds 4b and 6b, both containing benzenesulfonamide linked to N-, 10 bearing imidazole moiety, and 15 and 19b,c with a thiophene-2-carboxylic acid chain, exhibited high activity against Gram-positive and Gram-negative bacteria.
Thiophene derivatives are among the most important chemotherapeutic agents and are widely used (1, 2) . Thienopyrimidines occupy a special position among condensed heterocyclic compounds. They have been widely employed due to their activities as antitumor (3, 4) , antimetabolite (5), antiviral, anti-HIV-1 (6), antiproliferative (7), antimicrobial (10, 11) , analgesic and anti-infl ammatory (12, 13) agents, as well as kinase (8) and phospho-diesterase IV inhibitors (9) . Among these active compounds, thieno [3,2-d] pyrimidines have generated wide-spread interest due to their remarkable antitumor activities (3, 4, 14) . Thus, substituted thieno [3,2-d] pyrimidines exert pronounced activity as PI3K inhibitors (GDC-0941) and EGFR and VEGFR dual inhibitors, which are used in the treatment of cancers (15) (16) (17) . As a part of our continuing program on the synthesis of antimicrobial and antitumor compounds, we have earlier reported on a series of heterocyclic moieties that have biological activities (11) (12) (13) .
Furthermore, sulfonamide derivatives are an important class of compounds used as scaff olds in medicinal chemistry (11) in addition to triazole derivatives (18) , showing antibacterial (19) , antineoplastic (20) and antitubercular (21) activity. Recently, compounds bearing 1,2,4-triazole moieties have att racted great att ention owing to their anticancer value (22, 23) . The present work is an extension of our ongoing eff orts towards the synthesis and evaluation of novel thiophenes bearing biologically active sulfonamide, pyrole, pyrrolopyrimidine derivatives, and thieno [3,2-d] pyrimidine derivatives containing 1,2,4-triazole moiety, as antitumor and antibacterial agents. EXPERIMENTAL An Electrothermal 9100 series digital melting point apparatus (Shimadzu, Japan) was used for all measurements of melting points. For microanalytical data, a Vario Elementar apparatus (Shimadzu) was used. Elemental analyses of all compounds were within ± 0.4 % of theoretical values. IR spectra (KBr) were recorded on a Perkin Elmer 1650 spectrometer (USA) while 1 H NMR and 13 C NMR spectra were recorded on JEOL EX-300 and JEOL ECA-500 (Shimadzu) instruments, resp. Chemical shift s were expressed in ppm relative to SiMe 4 as internal standard in DMSO-d 6 as solvent. For mass spectra recording, a 70 eV Finnigan SSQ 7000 spectrometer (Thermo-Instrument System Incorporation, USA) was used. Purity of the compounds was checked by TLC using silica gel-coated aluminum plates (Merck, Germany). 3-Amino-5-(4-chlorophenyl)-thiophene-2-carboxylic acid (1) and other chemicals and solvents (Analar ≥ 99%) were purchased from Sigma-Aldrich (USA). Ciprofl oxacin and doxorubicin disks were supplied by the Pasteur Laboratory (Egypt). (2) . -3-Amino-5-(4-chlorophenyl)-thiophene-2-carboxylic acid (1, 15 g, 60 mmol) was suspended in 150 mL of absolute ethyl alcohol (99 %). Dry hydrogen chloride was passed through until the solution was saturated and became hot, then the reaction mixture was refl uxed for 2 h. When the reaction was complete, the solution was cooled and the mixture was diluted with 200 mL of water and made alkaline by sodium carbonate solution. A solid product crystallized from ethanol as white crystals.
Syntheses Ethyl 3-amino-5-(4-chlorophenyl)-thiophene-2-carboxylate

Ethyl 5-(4-chlorophenyl)-3-isothiocyanatothiophene-2-carboxylate (3)
-A mixture of compound 2 (2.81 g, 10 mmol) and thiophosgene (1.14 mL, 10 mmol) in dry chloroform (25 mL) was stirred under refl ux for 6 h. The solvent was evaporated and the solid obtained was recrystallized from ethanol as a deep yellow solid.
Ethyl-5-(4-chlorophenyl)-3-[N-(substituted) 4-(carbamothioyl)amino-benzenesulfonamide] thiophene-2-carboxylate derivatives (4a-c).
General procedure. -A mixture of compound 3 (3.24 g, 10 mmol) and 0.01 mol of the appropriate sulfa drug (sulfaguanidine, 2,6-dimethoxysulfadiazine or 3,4-dimethylsulfaiso-oxazole) in DMF (30 mL) was stirred under refl ux for 5 h. The reaction mixture was poured onto ice water and the obtained product was recrystallized from dioxane to give compounds 4a-c. The following compounds were prepared: derivatives (5a-c) . General procedure. -A mixture of 4a-c (10 mmol) and hydrazine hydrate (10 mL) in butanol (30 mL) was refl uxed for 5 h. Aft er cooling, the reaction mixture was poured onto ice water and the solid obtained was recrystallized from dioxane to give 5a-c. The following compounds were prepared:
General procedure. -A mixture of 5a-c (10 mmol) and 4-fl uorobenzaldehyde (1.24 g, 10 mmol) in glacial acetic acid (20 mL) containing fused sodium acetate (0.5 g) was heated under refl ux for 6 h. The solvent was concentrated and the residue was recrystallized from dioxane to give 6a-c. The following compounds were prepared: (8) . -A mixture of compound 2 (2.81 g, 10 mmol) and benzylamine (1.07 g, 10 mmol) in decalin (2.7 mL, 20 mmol) and triethylorthoformate (15 mL) was refl uxed for 16 h, the reaction mixture was cooled and fi ltered, the obtained solid was crystallized from ethanol as a pale-yellow powder. [3,2-d] pyrimidin-4(3H)-one (9) . -A mixture of compound 2 (2.81 g, 10 mmol), hydrazine hydrate (98 %, 2 mL) in absolute ethanol and triethylorthoformate (10 mL) was refl uxed for 10 h, the reaction mixture was cooled and fi ltered. The obtained solid was crystallized from ethanol as a pale-brown powder. (10) . -A mixture of compound 9 (2.78 g, 10 mmol), and 4-benzylidene-2-phenyl-4H-oxazol-5-one (2.49 g, 10 mmol) in glacial acetic acid (20 mL) containing fused sodium acetate (2 g) was refl uxed for 5 h. The reaction mixture was cooled and then poured onto cold water, the solid obtained was crystallized from DMF as a white powder. [2,3-e] [1, 2, 4] triazolo [1,5-c] pyrimidine-2(3H)-thione (11) . -A mixture of compound 9 (2.78 g, 10 mmol) and thiourea (0.76 g, 10 mmol) was fused over an oil bath at 220 °C for 30 min. The solid thus obtained was crystallized from ethanol as a yellow powder. [2,3-e] pyrimido [3,4-c] [1, 2, 4, 5] tetrazine (12) (24) . -A mixture of compound 9 (2.78 g, 10 mmol) and phosphorous pentasulfi de (2.66 g, 12 mmol) in pyridine (20 mL) was refl uxed for 12 h, the reaction mixture was concentrated and allowed to cool. The solid obtained was crystallized from ethanol as a white powder. (13) . -A mixture of 9 (2.78 g, 10 mmol) and phosphorous pentasulfi de (2.66 g, 12 mmol) in xylene (25 mL) was heated under refl ux for 5 h. The reaction mixture was hot fi ltered, the solid that separated from the fi ltrate crystallized from ethanol as a yellow powder. (14) . -A mixture of thiophene derivative 1 (2.53 g, 10 mmol) and phenacyl bromide (1.99 g, 10 mmol) was refl uxed in ethanol for 3 h. The solid obtained was fi ltered and crystallized from dioxane to give 14 as an orange powder. (15) . -A mixture of 14 (3.71 g, 10 mmol) and malononotrile (0.66 g, 10 mmol) in ethanol (30 mL) containing sodium ethoxide (0.5 g) was refl uxed for 5 h, the reaction mixture was cooled and acidifi ed with dil. HCl. The solid obtained was recrystallized from dioxane to give 15 as pale-yellow crystals. (16) . -A solution of 15 in acetic anhydride (30 mL) was refl uxed for 8 h, the reaction mixture was concentrated under reduced pressure and the solid obtained was crystallized from ethanol to give 16 as a white powder. (17) . -A mixture of 15 (4.19 g, 10 mmol) and succinic anhydride (1.10 g, 10 mmol) was fused at 220 °C in an oil bath for 15 min. The reaction mixture was triturated with ethanol and the solid obtained was crystallized from methanol to give 17 as brown crystals. (18) . -To a mixture of triethylorthoformate (1.48 g, 10 mmol) and acetic anhydride (20 mL), compound 15 (4.19 g, 10 mmol) was added and the reaction mixture was refl uxed for 5 h. The solvent was removed under reduced pressure and the separated solid was recrystallized from dioxane, to give 18 as a yellow powder.
3-Amino-6-(4-chlorophenyl)-thieno
6-(4-Chlorophenyl)-3-(5-benzylidene-2-phenyl-3,5-dihydro-4H-imidazol-4-one-3-yl) thieno[3,2-d]pyrimidin-4(3H)-one
8-(4-Chlorophenyl)-thieno
Bis-6,6'-(4-dichlorophenyl)-thieno
3-Amino-6-(4-chlorophenyl)-thieno[3,2-d]pyrimidin-4(3H)-thione
5-(4-Chlorophenyl)-3-[(2-oxo-2-phenylethyl)-amino]thiophene-2-carboxylic acid
3-(2-Amino-3-cyano-4-phenyl-1H-pyrrol-1-yl)-5-(4-chlorophenyl)-thiophene-2-carboxylic acid
5-(4-Chlorophenyl)-3-(2-methyl-4-oxo-5-phenyl-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidine-7-yl)-thiophene-2-carboxylic acid
3-(3-Cyano-2-(2,5-dioxopyrrolidin-1-yl)-4-phenyl-1H-pyrrol-1-yl)-5-(4-chlorophenyl)-thiophene-2-carboxylic acid
3-(3-Cyano-2-amino(ethoxymethylene)-4-phenyl-1H-pyrrol-1-yl)-5-(4-chlorophenyl)-thiophene-2-carboxylic acid
5-(4-Chlorophenyl)-{3-(4-substitutedphenyl)-9-phenyl-7H-pyrrolo[3,2-e][1,2,4] triazolo[4,3-c]-pyrimidin-7-yl}-thiophene-2-carboxylic acid (19a-c).
General procedure. -To a solution of 18 (4.75 g, 10 mmol) in absolute ethanol (50 mL), hydrazide derivative (10 mmol) was added. The reaction mixture was refl uxed for 4 h, concentrated, cooled and the solid product that 
Biological screening
Antitumor activity. -The majority of newly synthesized compounds were tested for in vitro anticancer activity against three human cancer cell lines [liver cancer (HepG-2), colon cancer (HT29) and lung cancer (NCI-H460)] using the MTT assay. The three human cancer cell lines were provided by the National Cancer Institute (NCI, Cairo, Egypt). Their growth as a monolayer was maintained in RPMI-1640 medium supplemented with 5 % heat inactivated FBS (fetal bovine serum), 2 mmol L -1 glutamine and antibiotics (penicillin 100 U mL -1 , streptomycin 100 μg mL , followed by 24-h incubation. The eff ect of the solvent DMSO on cell growth was evaluated by exposing untreated control cells to the maximum concentration of DMSO (0.5 %) used in each assay. Eff ects of the compounds on in vitro growth of human tumor cell lines was evaluated according to the procedure of the National Cancer Institute (NCI, USA), using sulforhodamine B as protein binding dye to assess cell growth (25) . Cells growing exponentially in 96-well plates were then exposed for 48 h to fi ve serial concentrations of each compound, starting from a maximum concentration of 150 μmol L -1
. Aft er this exposure period, adherent cells were fi xed, washed and stained. The bound stain was solubilized, the absorbance was measured and the growth inhibition of 50 % (GI 50 ) was calculated (26) . Doxorubicin was used as a reference compound (Table III) .
Antibacterial activity. -Antibacterial activity of the newly synthesized compounds was tested in vitro against the Gram-positive bacteria Staphylococcus aureus ATCC-1096, Streptococcus bovis ATCC-1030 and Gram-negative bacteria Chlamydia pneumoniae ATCC-1416 and Salmonella typhi ATCC 2453. All microorganisms were purchased from the American Type Culture Collection (Manassas, USA). The compounds were dissolved in DMSO and preliminarily tested for antibacterial activity using the agar disk diff usion technique (27) , microplate-wells (1 cm in diameter) and a solution of 100 μg mL -1 of the test compound. Compound-impregnated disks were placed on an agar plate containing a standard suspension of microorganisms. The plate was incubated for 24 h at 37 °C. Diameters of the zones of inhibition were measured with calipers or automated scanners and were compared to those of the standards (data not shown). Ciprofl oxacin (50 μg mL -1 , 150.9 μmol L -1 ) was used as a reference drug.
For determination of the minimum inhibitory concentration (MIC) by the serial plate dilution method (28), 5 mg of each test compound was dissolved in 1 mL of DMSO to prepare a stock solution. Serial dilutions were prepared from the stock solution. The plates were incubated at 37 °C for 24 h. MIC was the lowest concentration (expressed in μmol L -1 ) of the test compound that resulted in no visible growth on the plates. DMSO was used as a solvent control to ensure that the solvent had no eff ect on bacterial growth. Results of antibacterial activities are summarized in Table IV .
Table III. Eff ects of synthesized compounds on the growth of three human tumor cell lines
Compd.
GI 50 (μmol L Results are given as concentrations that were able to cause 50 % cell growth inhibition (GI 50 ) aft er continuous exposure for 48 h. Mean ± SEM of three independent experiments performed in duplicate.
RESULTS AND DISCUSSION
Chemistry
Thiophene-2-ethyl carboxylate derivative was the key intermediate for the synthesis of a novel series of thieno[3,2-d]pyrimidine and 3-[2-amino-3-cyano-4-phenyl]pyrazolo-5-(4-chlorophenyl)-thiophene-2-carboxylic acid derivatives to be screened as anticancer and antibacterial agents. The synthetic route of target compounds 2-13 is illustrated in Schemes Thionation of compound 9 by treatment with P 2 S 5 in pyridine gave unexpectedly new bis-6,6'-(4-dichlorophenyl)-thieno [2,3-e] pyrimido [3,4-c] [1, 2, 4, 5] tetrazine (12) rather than the expected monothione derivative (13) . IR spectrum of compound 12 showed the absence of NH 2 , while the IR spectrum of compound 13 showed that the NH 2 group was still present, in addition to the presence of C=S at 1265 cm -1 (Scheme 2). On repeating the same reaction in xylene, the mono thione derivative (13) was obtained based on the IR data, which showed the presence of NH 2 and C=S bands. 
Antitumor activity and structure a ctivity relationship
The eff ect of newly synthesized compounds was evaluated through in vitro growth of three human tumor cell lines representing diff erent tumor types, namely, liver cancer (HepG-2), colon cancer (HT-29) and lung cancer (NCI-H460), aft er continuous exposure for 48 h. The results summarized in Table III show that most of the tested compounds exhibited marked activity compared to doxorubicin. , resp.) against the three tumor cell lines. Such high activity of both compounds is att ributed to the presence of pyrrolopyrimidine moiety at position 3 in the thiophene derivative 16 but is also due to the presence of triazolopyrimidine moiety as in compound 19b. In addition, the presence of stronger electron-withdrawing substituents (chloro) in the para-position of the phenyl ring might be responsible for enhancing the growth inhibition activity.
Compounds 19a and 19c exhibited moderate to good antitumor activity due to the electronic nature of the substituent on the phenyl ring att ached to [1, 3, 4] ; activity of these compounds is probably due to the presence of a substituent in the phenyl ring att ached to thieno[3,2-d]pyrimidine such as (N-carbamimidoyl and N-pyrimidinyl) benzenesulfonamide in 5a,b, [1, 2, 4] triazolopyrimidine att ached to p-fl uorophenyl in 6b and thioxotriazole moiety fused with the pyrimidine ring in 11. Furthermore, compounds 4a, 5c, 6a,c, 9, 10, 14, 17 and 18 exhibited moderate to low antitumor activity on the three tumor cell lines, while compounds 4c and 12 exhibited very low antitumor activity.
Antibacterial activity
Compounds 4a-c, 5a-c, 6a-c, 8-12 and 14-19 were also tested for antibacterial activity (Table IV) , while compounds 8 and 9 exhibited promising activity against all strains. This activity may be att ributed to the presence of N-imidazole moiety at pyrimidine in 10, N-benzyl group in compound 8 and N-amino group at pyrimidine in compound 9.
Compounds 4a, 5a-c, 6a,c, 11 and 14 showed promising activity against all the tested bacteria, and this activity may be due to the presence of imido group in 4a, the formation of fused N-amino-thienopyrimidine skeleton as in 5a-c, in addition to the presence of [1, 2, 4] triazolopyrimidine in 6a-c and [1,2,4]triazolopyrimidine in 11. Also, the presence of oxo-phenylethylamino att ached to the thiophene ring in 14 seems to increase the antibacterial activity. Moreover, compound 4c exhibited good activity against Gram-negative bacteria with MIC of 4 μmol L -1 and moderate activity against Gram-positive bacteria, while compounds 12, 17, 18 and 19a displayed low activity against all the tested bacteria.
CONCLUSIONS
In the present work, we synthesized some novel thiophenes bearing sulfonamide, pyrrole, pyrrolopyrimidine structures, and thieno [3,2- Activities of these compounds were strongly dependent on the basic skeleton of the molecules and the nature of the heterocyclic ring att ached to the thiophene unit as well as on the nature of the substituent at the thiophene unit.
